Details: A presentation followed by a Q&A. The seminar is open all, so please share with anyone who might be interested.
In an upcoming publication in Nature Biotechnology, Dr Sheila Keating and her team have demonstrated the technology to capture entire immune repertoires from infected or vaccinated individuals, to be used to treat difficult to treat infections - and have demonstrated this work with COVID and respiratory bacterial infections. In this talk, Sheila will describe the technology and will map out potential pathways for developing passive immune therapeutics that will not only treat but also help to prime immune responses to protect against future infections.
Location: Online via Microsoft Teams
Register: You can register using the form below. Once registered, we will send you a link to the Teams Meeting via an email.
Time and Date: 16:00 GMT, 11 March 2021
Dr Sheila Keating is a VALIDATE Network Investigator Adjunct Associate Professor at GigaGen and the University California San Francisco. Over the past 15 years, Sheila's work has focused on understanding cellular and humoral immune responses to vaccines and infectious diseases and, more recently, has focused on using high throughput immune assays to measure biomarkers of immune response or pathology in a number of studies ranging from HIV, HCV, HBV vaccine breakthrough, Chagas, West Nile Virus, cardiovascular disease, neuropathology and many other areas.